The seven-page document of guidelines, which is still technically a draft subject to change, outlines the agency’s “current thinking” on a range of issues relevant to research and drug development. It provides some basic business and scientific guidance around cannabis. This includes how best to calculate the amount of THC in CBD oil, for example. But it doesn’t provide a lot of valuable information. In the most glaring instances of nonsensical oversight, it fails to state any rules or regulations for cannabis businesses. Nor does it explain how the agency will guide cannabis research in America.
New guidelines have been eagerly anticipated for decades. Cannabis research has been stymied by a slow and ridiculous set of laws that have prevented researchers from producing good work in a timely manner.
Currently, anyone attempting cannabis research in America must buy their weed from a single farm in Mississippi. And the product isn’t very good. And limited. In fact, the potency is never higher than eight per cent. Not a very good representation of the cannabis medical cannabis patients buy every day from dispensaries or the black market.
The nation’s only legal research-grade cannabis supplier also operates at a glacial pace, and often sends out moldy, unusable, products to scientists to use in their research. The faults of the program are well known, and the latest FDA guidelines re-affirm the government’s commitment to keeping its citizens ignorant and sick by gumming up the machinery of cannabis research.
Read more at rxleaf.com